Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting.

Oncol Ther · 2020 · PMC7683690 · PMID 32700045

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significancep = 0.12not close (p > 0.1)

For the abiraterone + ADT arm of the LATITUDE trial, the OS advantage did not reach statistical significance by post hoc analysis in the subset of patients who were defined as having low-volume disease (HR 0.72, p = 0.12) [ 17 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.